Our results are in accordance with previous reports that demonstrated that a combination of MEK and ROCK inhibitors not only reduced NRAS mutant melanoma cell viability in vitro but also reduced tumor growth in vivo [12]. The gene discussed is MAP2K7; the disease is melanoma.